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To The Editor: On 6th October the Nobel Assembly at 
Karolinska Institute, Stockholm, Sweden announced The 
Nobel Prize in Physiology or Medicine for 2008, and 
virologists all over the world had a lot to cheer about. 
Three “virus hunters” who worked with two different 
viruses brought honour to virology. Harald zur Hausen for 
his discovery of "human papilloma viruses (HPV) causing 
cervical cancer” and Françoise Barré-Sinoussi and Luc 
Montagnier for their discovery of "human 
immunodeficiency virus (HIV)" have been chosen for this 
year’s award [1]. All  three will deliver the Nobel Lectures 
on Sunday 7th  December. The entire scientific community 
is waiting to hear about their encounters, relentless 
battles, and exploits against these pathogens. Their 
discoveries have paved the way for an astonishing 
progress in preventing HPV induced cervical cancer, and 
more zeal to find a successful vaccine against the HIV. 
Nobel prizes can be split between a maximum of three 
individuals and it indeed is a great irony that a stalwart 
like Robert Gallo, the “co-discoverer” of HIV had to be left 
out on technical or other reasons best known to the Nobel 
Committee .The Franco-American virus war between Luc 
Montaigner and Robert Gallo which started in 1984 and 
ended in 1987 is now part of scientific folklore. It is now 
known that the “French” lymphadenopathy associated 
virus (LAV) and “American” human T-cell leukemia 
/lymphoma virus type III B ( HTLV-IIIB ) were indeed one 
and the same, which is now known as HIV. Many among 
the scientific community, and foe turned friend Luc 
Montaigner himself, acknowledged that Robert Gallo 
deserved to be the third recipient ,  had the Nobel 
Committee honoured only those who contributed to the 
discovery of HIV [2].  
 
About half a century ago when there was considerable 
scepticism whether viruses cause cancer, Harald zur 
Hausen postulated a role for oncogenic human papilloma 
virus ( HPV ) in cervical carcinoma . In 1983 he first 
identified HPA-DNA in cervix cancer biopsies, and thus the 
new, tumorigenic HPV16. In 1984 he cloned HPV16 and 
18 and thus made these viruses available to the scientific 
community. His pioneering work demonstrated novel 
properties of HPV that lead to an understanding of 
mechanisms for papilloma virus- induced carcinogenesis 
and predisposing factors for viral persistence and cellular 
transformation [3]. HPV infection causes >550,000 cases 
of cervical and anogenital cancer worldwide annually, and 
is responsible for 99.7% of cervical cancer cases and an 
estimated 5% of all cancers worldwide [4,5)]. Of the more 
than 100 HPV types known, HPV 16 and HPV 18 are 
responsible for approximately 70% of all invasive cervical 
cancers worldwide , and HPV types 6 and 11 cause 
approximately 90% of cases of genital warts [4, 6].  
 
The development of the human papilloma virus vaccine 
is a major milestone in the development of cancer 
vaccines. Following the success of several clinical trials, 
pharmaceutical giant Merck in 2006 submitted a successful 
Biologics License Application for its prophylactic HPV virus 
like particle (VLP) vaccine Gardasil TM to the US Food and 
Drug Administration. Subsequently, Gardasil TM received a 
European license, and many other countries also 
permitted its licensing. This vaccine for girls and women 
aged 9-26 years, protect against HPV types 6/11/16/18. 
The second prophylactic HPV vaccine Cervarix TM, 
manufactured by GlaxoSmithKline against HPV types 16 
and 18 has been licensed this year [6]. A recent 
systematic review of randomized controlled trials of 
prophylactic HPV vaccination have indicated that among 
women aged 15-25 years not previously infected with 
vaccine type HPV strains, prophylactic HPV vaccination 
was 96%-100% effective in  preventing HPV 6/11/16/18-
related cervical and anogenital precancers and genital 
warts [7].  
 
Despite the remarkable promise of the current 
prophylactic HPV vaccines, their introduction into 
developing countries will present unique and considerable 
challenges. These include lack of national data on type- 
specific HPV incidence, poor public awareness and 
attitudes toward HPV vaccination, complexities of vaccine 
introduction, and sociocultural issues related to HPV 
vaccines. A recent study in the United Kingdom to assess 
public knowledge about HPV and cervical cancer indicated 
that even in this developed country, the majority of 
participants had no knowledge about the problem or 
benefits of the vaccine [8]. A multifaceted and coordinated 
strategy would be needed to increase awareness and 
implementation of HPV vaccination programmes.  Several 
international organizations such as PATH, International 
Agency for Research on Cancer, World Health 
Organization (WHO) and the Bill and Melinda Gates 
Foundation are playing an active role in introducing HPV 
vaccines in developing countries 
 
The history of AIDS is a short one, but the 
consequences of the global AIDS epidemic has been 
nothing less than catastrophic. Since its first description in 
the 1980s among homosexual men in San Fransisco, USA, 
25 million have fallen victim to the deadly virus, and 
millions are living with the HIV infection worldwide [9]. 
Table 1 indicates the latest statistics on the world 
epidemic of AIDS and HIV which were published by 
UNAIDS/ WHO in July 2008, and refer to the end of 2007 
[10].  Regional statistics for HIV and AIDS show that 
among the global total of 33 million adults and children 
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living with HIV/AIDS, 22 million were in Sub-Saharan 
Africa. In three southern African countries national adult 
HIV prevalence rate now exceeds 20%. These countries 
are Botswana (23.9%), Lesotho (23.2%) and Swaziland 
(26.1%). A national survey conducted in 2004–2005 with 
67,711 participants randomly recruited from across Libya 
showed that HIV prevalence among the general 
population had reached 0.67% in Alkoufra governorate in 
the south-east of the country, 0.4% in Tripoli compared 
with national prevalence of 0.13% [11]. Unlike the 
tremendous success achieved in developing the 
prophylactic vaccine against HPV, we are no nearer a cure 
and certainly years away from a vaccine against HIV [12]. 
Cost effective interventions such as male and female 
condom promotion, sex worker interventions, AIDS 
education in schools, voluntary counseling and testing, 
blood supply safety measures, encouraging partner 
reduction, and prevention of mother-to-child transmission 
can play a major role in containing the spread of this 
epidemic. The World AIDS day is observed every year on 
December 1st. The World Health Organization established 
World AIDS Day in 1988. The twentieth anniversary this 
year is another reminder for all of us to collectively work 
to raise awareness and focus attention on the global AIDS 
epidemic. From the bottom of our hearts let us thank the 
“virus hunters” for their great service to humanity and 
hope that their tribe grows to conquer these deadly 
pathogens. 
 
Table 1 Global HIV /AIDS estimates, end of 2007 
  Estimate in 
millions  
Range in 
millions  
People living with HIV/ AIDS in 
2007  
33.0     30.3 – 36.1    
Adults living with HIV/ AIDS in 
2007  
30.8    28.2 – 34.0    
Women living with HIV/ AIDS in 
2007  
15.5     14.2 – 16.9    
Children living with HIV/ AIDS in 
2007  
2.0    1.9 – 2.3    
People newly infected with HIV in 
2007  
2.7     2.2 – 3.2    
Children newly infected with HIV 
in 2007  
0.37     0.33 – 0.41    
AIDS deaths in 2007   2.0     1.8 – 2.3    
Child AIDS deaths in 2007   0.27     0.25- 0.29    
UNAIDS/WHO in July 2008 
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